Efficacy and safety of obinutuzumab combined with short-course dexamethasone for relapsed immune thrombocytopenia after treatment with rituximab
10.3760/cma.j.cn115356-20250423-00065
- VernacularTitle:奥妥珠单抗联合短程地塞米松对利妥昔单抗治疗后复发免疫性血小板减少症的有效性及安全性
- Author:
Xiaotong CHEN
1
;
Yanqiu ZHAO
;
Qi LI
;
Shengjin FAN
Author Information
1. 哈尔滨医科大学附属第一医院血液科，哈尔滨 150070
- Keywords:
Immune thrombocytopenia;
Relapse;
Obinutuzumab;
Platelet antibodies;
Lymphocyte subsets
- From:
Journal of Leukemia & Lymphoma
2025;34(10):597-600
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of obinutuzumab combined with short-course dexamethasone in patients with relapsed immune thrombocytopenia (ITP) who had previously been treated with rituximab.Methods:A retrospective case series study was conducted. A total of 8 patients with relapsed ITP after treatment with rituximab who received obinutuzumab combined with short-course dexamethasone between January 2023 and January 2024 in the First Affiliated Hospital of Harbin Medical University were collected. The clinical characteristics, changes in platelet counts, changes in peripheral blood B-lymphocyte counts, treatment outcome and treatment-related adverse events were analyzed.Results:There were 1 male and 7 females in 8 patients with relapsed ITP after treatment with rituximab. The median age [ M ( Q1, Q3)] of the 8 enrolled patients was 52.5 (40.5, 56.0) years. The median relapsed times was 2.0 (2.0, 2.5) times and the median course of disease was 16.0 (13.0, 18.5) months. The platelet count increased from 8.73 (5.79, 11.65)×10 9/L pre-treatment to 180.00 (83.40, 255.00)×10 9/L post-treatment, and the difference was statistically significant ( Z = -2.37, P = 0.018); conversely, peripheral blood B-lymphocyte count decreased from 322.59 (148.29, 403.07) × 10 9/L pre-treatment to 1.23 (0.57, 1.76) ×10 9/L post-treatment, and the difference was statistically significant ( Z = -2.52, P = 0.012). After obinutuzumab and short-course dexamethasone treatment, 6 patients achieved complete remission, 1 case showed response, and 1 case had no response. No severe adverse events were observed during treatment and follow-up in all patients. Conclusions:Obinutuzumab combined with short-course dexamethasone appears to be effective in treating relapsed ITP patients after treatment with rituximab, and its safety is good.
